



Coding stage : Session 8

Breast Cancer

Liesbet Van Eycken


Preface	XII
Acknowledgments	XIV
Organizations Associated with the TNM System	
Members of UICC Committees Associated with the TNM System	XVI
Section Editors	XVII

Introduction 1**Head and Neck Tumours** 17

Lip and Oral Cavity	18
Pharynx	22
Larynx	31
Nasal Cavity and Paranasal Sinuses	36
Unknown Primary – Cervical Nodes	40
Malignant Melanoma of Upper Aerodigestive Tract	45
Major Salivary Glands	47
Thyroid Gland	51

Digestive System Tumours 55

Oesophagus and Oesophagogastric Junction	57
Stomach	63
Small Intestine	67
Appendix	70
Colon and Rectum	73
Anal Canal and Perianal Skin	77
Liver	80
Intrahepatic Bile Ducts	83
Gallbladder	85
Perihilar Bile Ducts	87
Distal Extrahepatic Bile Duct	89
Ampulla of Vater	91



Pancreas	93
Well-Differentiated Neuroendocrine Tumours of the Gastrointestinal Tract	96
Lung, Pleural, and Thymic Tumours	105
Lung	106
Pleural Mesothelioma	113
Thymic Tumours	115

Tumours of Bone and Soft Tissues 119

Bone	120
Soft Tissues	124
Gastrointestinal Stromal Tumour (GIST)	127

Skin Tumours 131

Carcinoma of Skin	133
Skin Carcinoma of the Head and Neck	136
Carcinoma of Skin of the Eyelid	139
Malignant Melanoma of Skin	142
Merkel Cell Carcinoma of Skin	147

Breast Tumours 151**Gynaecological Tumours** 159

Vulva	161
Vagina	164
Cervix Uteri	166
Uterus – Endometrium	171
Uterine Sarcomas	175
Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma	179
Gestational Trophoblastic Neoplasms	184

Urological Tumours 187

Penis	188
Prostate	191
Testis	195
Kidney	199

Renal Pelvis and Ureter	202
Urinary Bladder	204
Urethra	208

Adrenal Cortex 211

Ophthalmic Tumours	215
Carcinoma of Conjunctiva	216
Malignant Melanoma of Conjunctiva	218
Malignant Melanoma of Uvea	221
Retinoblastoma	226
Sarcoma of Orbit	230
Carcinoma of Lacrimal Gland	232

Hodgkin Lymphoma 235**Non-Hodgkin Lymphomas** 239**Essential TNM** 241

Paediatric Tumours	247
Gastrointestinal Tumours	247
Bone and Soft Tissue Tumours	248
Gynaecological Tumours	249
Urological Tumours	250
Ophthalmic Tumours	251
Malignant Lymphoma	252
Central Nervous System	252

(prim. cut)

Breast

- **Topography** C50, male and female
- **Histology:** All carcinomas
 - Excluded: phyllodes tumours, sarcoma, lymphoma
- **Histopathological grade:**
 - Nottingham histological score is recommended
- **Bilateral tumour:** 2 TNM's !
- **Read the 'notes' ...!**




T-categories: size and extension

- TX
- T0
- Tis (DCIS) (LCIS) (PAGET)

- **T1** ≤ 2 cm
T 1mi ≤ 0.1 cm
microinvasion
- **T2** >2 cm, ≤ 5 cm
T 1a > 0.1– 0.5 cm
T 1b > 0.5 cm–1.0 cm
T 1c > 1.0–2.0 cm
- **T3** >5 cm


- **Multifocal tumour**

- Use the 'm' suffix (or number): e.g. T1b(m) or T1b(2)
- Take the dimension of the largest lesion
- Combination of invasive and in situ lesion=> only the dimension of the invasive



T-categories: size and extension (2)

- **T4** involving chest wall and/or skin



T 4a Chest wall (ribs, intercostal muscles, m. serratus anterior, NOT m. pectoralis)

T 4b Skin ulceration, satellite skin nodules, skin oedema

T 4c Both T4a and T4b


T 4d Inflammatory carcinoma

Notes:

- 1) Dimpling of the skin, nipple retraction => does not affect the T-category
- 2) Peau d'orange - skin oedema T4b
 - cT and pT => take into account clinical aspect for pT
 - Clinical + surgical + pathological info!
- 3) Clinically mastitis carcinomatosa (cT4d) but skin biopsy negative and no localized tumour => pTX.
- 4) pT: Invasion of the dermis alone is not enough to qualify as T4

Source of figure : Union for International Cancer Control - TNM Atlas Illustrated Guide to the TNM Classification of Malignant Tumours - Sixth Edition edited by Ch. Wittekind/h. Asamura/ L.H. Sobin - Published by Wiley Blackwell
Permission kindly granted by Wiley on 26/09/2018.

N-category values and principles (1)



The regional lymph nodes

1. *Axillary* (ipsilateral)
 - i) *Level I* (low-axilla)
 - (ii) *Level II* (mid-axilla)
 - (iii) *Level III* (apical axilla)
2. *Infraclavicular (subclavicular)* (ipsilateral).
3. *Internal mammary* (ipsilateral)
4. *Supraclavicular* (ipsilateral).

Note:

1. **cN is different from pN !**
2. **No pN if no resection of the primary tumour => use cN**
3. **Avoid cNX**
4. **Intramammary node => N category (level I)**
5. **pN: at least axillary lymph node level I, 6 nodes recommended**

N-category


cN

pN


	cN	pN	
	N1 Movable axillary level I/II	<p>pN1 Micrometastasis, 1–3 axillary nodes</p> <p>pN1mi Micrometastasis > 0.2–2 mm</p> <p>pN1a 1–3 axillary nodes (at least one > 2 mm)</p> <p>pN1b Internal mammary nodes</p> <p>pN1c 1–3 axillary nodes and internal</p>	Not clinically detected!
Clinically detected!	N2a Axillary, fixed or matted	pN2a 4–9 axillary nodes (at least one > 2 mm)	
	N2b Internal mammary nodes, clinically detected, ^d without axillary nodes	pN2b Internal mammary nodes, <u>clinically detected</u> , without axillary nodes	Clinically detected!
	N3a Axillary level III, infraclavicular	pN3a Axillary ipsilateral ≥ 10 (at least one > 2 mm), infraclavicular, level III lymph nodes	
	N3b Axillary and internal mammary	pN3b Internal mammary nodes and axillary nodes, > 3 axillary nodes and in internal mammary nodes with microscopic or macroscopic metastasis detected by sentinel node biopsy but not clinically detected	
	N3c Supraclavicular lymph nodes	pN3c Ipsilateral supraclavicular lymph nodes	

pN: Macrometastasis versus Micrometastasis versus ITC


Macrometastasis pN1



Micrometastasis pN1mi



ITC pN0(i+)




AJCC, Cancer Staging manual, 8th edition, Breast

<https://cancerstaging.org/references-tools/deskreferences/Pages/Breast-Cancer-Staging.aspx>

N-category

- **Micrometastasis in a lymph node** → pN1(mi) >0.2mm but none larger than 2.0 mm
- **Isolated tumour cells** (<0.2 mm or <200 cells/cross-section): ITC's
 - IHC pos/neg (morphological technique) => **pN0(i+)** or **pN0(i-)**
 - Molecular technique => pN0 (mol+)
- **Sn: Sentinel node**
 - (p)NX(sn)
 - (p)N0(sn)
 - (p)N1(sn) : sentinel lymph node metastasis (at least one node >0.2 mm)
- **ypN = pN categories**



Use of the TNM after Neoadjuvant Therapy: **ypTNM**

- **y**: Patient treated with neoadjuvant therapy (before surgery)
- **Neoadjuvant therapy**: systemic therapy (chemotherapy, hormone therapy, immunotherapy) and/or radiotherapy, given before surgery.
 - E.g. also endocrine therapy combined with anti-Her2 therapy
- **ypTNM**: Histopathological examination of surgical resection after neoadjuvant therapy => 'response' to therapy
- **ypT/ypN** = pT/pN categories
- **ypT - ypN**
 - should be based on the measurement of the **largest contiguous focus** of residual invasive cancer, if any. Treatment associated fibrosis, scars is not taken into account.

TNM Breast cancer: UICC – AJCC

- General aim UICC and AJCC TNM: there should be as little difference as possible
- UICC effective as from 2017 – AJCC 2018: Note the edition used
- Identical in the definitions of the T, N and M categories
 - Exception: LCIS has been excluded in the AJCC 8th edition
- Tumour measurement: Rounding is different
- AJCC introduced 'prognostic groups', revised November 2017
 - T, N, M and ER, PR, Her-2, Grade => Prognostic group
 - Modification of pathologic prognostic stage possible with results of genomic profiles (not obligatory to be used)

